← Leaderboards
Owen B. McManus
Q-State Biosciences, Inc.
$4,277,104
Attributed
$6,598,952
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2018–22$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,598,952 · 4
By mechanism
R44$6,071,313 · 3
R43$527,639 · 1
Top collaborators
- Hongkang Zhang4 shared
- Christina Marie Ambrosi2 shared
- Pin Liu2 shared
Most similar at Q-State Biosciences, Inc.
Same institution · by research overlap
- Christina Marie Ambrosi$263,820
- Graham Thomas Dempsey$4,974,932
- Eric White$171,519
- Luis Alberto Williams$1,618,454
Others in their field
Other Emerging Leaders on “Phenotype”
- Leonard Freedman · Leidos Biomedical Research, Inc.$68,463,085
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$28,580,688
- Evan Z Macosko · Broad Institute, Inc.$28,218,682
- Badri N Vardarajan · University Of Miami School Of Medicine$23,982,327
Research focus
PhenotypeResponseNeuronsCellsVoltageElectrophysiology (Science)ProteinsNeuronal ExcitabilityToxic EffectAfferent NeuronsPain ModelInflammation MediatorsTemporal MeasurementOpioidOpticsSpinal GangliaIn VitroDrug KineticsPainMedicalIn VivoRattusTechnologyPharmaceutical Preparations
Grant awards (11)
Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets$995,305
R44 · FY2022 · CA
Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets$1,000,001
R44 · FY2021 · CA
A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology.$696,518
R44 · FY2021 · AR
An antisense oligonucleotide therapy for KCNT1 based epileptic encephalopathies$76,089
R43 · FY2021 · NS
An all-optical electrophysiology platform for the discovery of pain therapeutics$1,000,946
R44 · FY2020 · NS · contact PI
A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology.$892,810
R44 · FY2020 · AR
An antisense oligonucleotide therapy for KCNT1 based epileptic encephalopathies$451,550
R43 · FY2020 · NS
Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets$300,728
R44 · FY2020 · CA
An all-optical electrophysiology platform for the discovery of pain therapeutics$731,940
R44 · FY2019 · NS · contact PI
A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology.$230,695
R44 · FY2019 · AR
An all-optical electrophysiology platform for the discovery of pain therapeutics$222,370
R44 · FY2018 · NS · contact PI